nonapeptide

Nonapeptide-1 acetate salt (158563-45-2 free base) (Melanostatine-5 acetate salt) , a peptide hormone, is a potent α-Melanocyte-stimulating hormone (α-MSH) antagonist, with an IC50 of 11 nM. Nonapeptide-1 acetate salt (158563-45-2 free base) , a peptide hormone, is a potent α-Melanocyte-stimulating hormone (α-MSH) antagonist, with an IC50 of 11 nM.

Nonapeptide-1 (Melanostatine™ 5) can inhibit the synthesis of melanin, which makes it of interest for treating certain skin conditions.

Polymyxin B nonapeptide acetate is a cationic cyclic peptide. Polyxin B nonapeptide is a derivative produced by enzymatic cleavage of polyxin B. Compared with polyxin B, polyxin B nonapeptide has low toxicity, lacks bactericidal activity and still has the

Polymyxin B nonapeptide, a cationic cyclic peptide derived by enzymatic processing from the naturally occurring peptide polymyxin B, is able to increase the permeability of the outer membrane of Gram-negative bacteria toward hydrophobic antibiotics probab

SP-346 nonapeptide is a pipecolic acid substituted nonapeptide.

Polymyxin B nonapeptide TFA is a useful organic compound for research related to life sciences and the catalog number is T64687.

V-9-M Cholecystokinin nonapeptide (Prepro CCK Fragment V-9-M) is a precursor compound of cholecystokinin (CCK). Cholecystokinin (CCK) is a brain-intestinal peptide that stimulates gallbladder contraction and pancreatic exocrine. It can be extracted from the small intestine of dogs and cats and can cause gallbladder contraction.

Nonapeptide-1 (Melanostatine-5) acetate salt, a peptide hormone, functions as a selective and competitive antagonist of the melanocortin 1 receptor (MC1R) with a binding affinity (K i) of 40 nM. It effectively inhibits α-MSH-induced increases in intracellular cyclic AMP (cAMP) and melanosome dispersion in melanocytes, showcasing inhibitory concentrations (IC 50) of 2.5 nM and 11 nM, respectively. By inhibiting melanin synthesis, Nonapeptide-1 acetate salt finds application in research related to skin pigmentation, adrenal gland steroid production regulation, and skin cancer [1] [2] [3].

Vasopressin acetate, a cyclic nonapeptide, is synthesized centrally in the hypothalamus. Vasopressin acetate acts as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors.

Substance P 1-9 aceate is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.

Hemopressin (rat) acetate is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB2 cannabinoid receptors. Hemopressin exerts antinocicep

p5 Ligand for Dnak and DnaJ acetate is a nonapeptide. It is a high-affinity ligand for DnaK (E. coli Hsp70) and DnaJ (E. coli Hsp40).

Chemerin-9 (149-157) acetate, The nonapeptide 149,YFPGQFAFS157 (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR.the natural ligand of C

Hemopressin (human, mouse) acetate is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts an

TCMCB07, a cyclic nonapeptide, serves as an orally active, brain-penetrant antagonist of the melanocortin receptor 4 (MC4R), with significant implications in the management of cachexia [1].

Crustacean cardioactive peptide (CCAP) is a highly conserved, amidated cyclic nonapeptide with the primary structure PFCNAFTGC-NH2 (ProPheCysAsnAlaPheTyrGlyCys-NH2) and a disulfide bridge between Cys3 and Cys9. It is found in crustaceans and insects where

TPNQRQNVC, a nonapeptide epitope of HLA-B0702, induces a CD8+ T cell immune response [1].

TCMCB07 TFA is a cyclic nonapeptide and an orally active, brain-penetrating antagonist of the melanocortin receptor 4 (MC4R), playing a significant role in managing cachexia [1].

Bradykinin analog nonapeptide. Reverse sequence of Bradykinin (Cat.No. 3004). Exhibits no significant kinin activity. Can be used as a negative control. Lande (1962) Retrobradykinin: a peptide with the reverse sequence of bradykinin. J.Org.Chem. 27 4558

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].

Tyrosinase (192-200), a human mouse nonapeptide, is recognizable by cytolytic T cells (CTL) on the HLA-B44 molecule and is utilized in the research of melanoma-associated cancers [1].

Cyclolinopeptide A is a cyclic nonapeptide extracted from linseed oil.

TAK-683 acetate is a nonapeptide metastin analog and a potent full agonist of the KISS1 receptor (KISS1R), exhibiting IC 50 =170 pM and enhanced metabolic stability. This compound shows agonistic activities towards KISS1R, with EC 50 values of 0.96 nM and 1.6 nM for human and rat KISS1R, respectively. TAK-683 acetate effectively depletes GnRH in the hypothalamus and reduces plasma levels of FSH, LH, and testosterone in vivo, showcasing its potential for hormone-dependent prostate cancer research.

CooP, a linear glioblastoma-targeting nonapeptide, interacts with the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) found in glioblastoma cells and their associated blood vessels. This interaction facilitates the targeted delivery of chemotherapy and various nanoparticles [1].

Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. It acts on particular cells of the pituitary gland called gonadotropes when present in the bloodstream. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

TAK-683 is an effective full KISS1 receptor agonist (IC50=170 pM). TAK-683 is a nonapeptide metastin analog, shows agonistic activities to KISS1R (EC50: 0.96 nM and 1.6 nM for human and rat, respectively).

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), acts as an antioxidant targeting mitochondria. It inhibits mitochondrial permeability transition (MPT), exhibiting anti-diabetic and cardioprotective effects [1].

Hemopressin TFA, a nonapeptide originating from the α1-chain of hemoglobin and initially isolated from rat brain homogenates, is an orally active, selective inverse agonist of CB1 cannabinoid receptors that demonstrates antinociceptive effects in inflammatory pain models [1] [2].

Chemerin-9 (149-157) TFA, the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR[1].

Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

The nonapeptide 149,YFPGQFAFS157 (chemerin-9), corresponding to the C terminus of processed chemerin, retained most of the activity of the full-size protein, with regard to agonism toward the chemerinR.the natural ligand of ChemR23 (chemerinR).

Substance P (1-9) is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder. Subtance P is responsible for a number of excitatory effects on both central and peripheral neurons.

TAK-683 TFA, a potent full KISS1 receptor (KISS1R) agonist with a half-maximal inhibitory concentration (IC50) of 170 pM, exhibits enhanced metabolic stability. As a nonapeptide metastin analog, it demonstrates agonistic activities towards KISS1R, with effective concentration (EC50) values of 0.96 nM for humans and 1.6 nM for rats. In vivo, TAK-683 TFA reduces gonadotropin-releasing hormone (GnRH) levels in the hypothalamus and decreases plasma follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels. Given these effects, TAK-683 TFA holds promise for research into hormone-dependent prostate cancer.

Atosiban (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Antiflammin P2 is a nonapeptide fragment of lipocortin I which has no phospholipase A2 inhibitory and anti-inflammatory activity.